Skip to content

US · APYX · MEDICAL - SPECIALTIES

Apyx Medical Corporation (APYX) intrinsic value and stock valuation

$2.40as of 2026-11-21 · Mkt cap 174.34M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Apyx Medical Corporation DCF and intrinsic value

InvestorsCraft values APYX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from APYX’s statements →

Apyx Medical Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Clearwater, FL 33760-4004 apyxmedical.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$52.8M+13.8% 5y CAGRd
20112025
Net income
-$-11.21M
20112025
Free cash flow
-$-9.12M
20112025
Total equity
$14.8M-25.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$52.8M$48.1M$52.4M$44.5M$48.5M
Operating income-$-6.45M-$-18.84M-$-17.26M-$-23.56M-$-14.45M
Net income-$-11.21M-$-23.46M-$-18.71M-$-23.18M-$-15.17M
EPSd-$-265.89K-$-660.1K-$-540.44K-$-671.49K-$-441.89K
Operating cash flow-$-8M-$-18.05M-$-5.25M-$-20.28M-$-10.45M
Capital expenditure-$-1.11M-$-720K-$-530K-$-1.01M-$-720K
Free cash flow-$-9.12M-$-18.77M-$-5.78M-$-21.29M-$-11.17M
Total assets$66.8M$64.8M$79.2M$51.8M$68.7M
Total debt$39.3M$38.8M$38.5M$800K$300K
Net debt$7.6M$7.02M-$-5.15M-$-9.4M-$-30.57M
Total equity$14.8M$14.3M$26.9M$37.8M$54M
Cash and short-term investments$31.7M$31.7M$43.7M$10.2M$30.9M
Income statement
20252024202320222021
Revenue$52.8M$48.1M$52.4M$44.5M$48.5M
Cost of revenue$33.8M$18.7M$18.6M$15.4M$14.9M
Gross profit$19M$29.4M$33.8M$29.1M$33.6M
Research and development expenses$3.37M$5.08M$4.84M$4.54M$4.32M
Selling, general and administrative expenses$36.1M$43.1M$48.9M$48.2M$43.7M
Other expenses-$-14.01M$0.00-$-2.69M$0.00$0.00
Operating expenses$25.5M$48.2M$51M$52.7M$48.1M
Cost and expenses$59.3M$67M$69.6M$68.1M$63M
Interest income$1.11M$1.61M$920K$160K$10K
Interest expense$5.59M$5.91M$2.48M$10K$10K
Depreciation and amortization$660K$600K$690K$890K$900K
Ebitda-$-4.59M-$-16.8M-$-18.11M-$-22.01M-$-13.91M
Operating income-$-6.45M-$-18.84M-$-17.26M-$-23.56M-$-14.45M
Total other income/expenses, net-$-4.39M-$-4.46M-$-4.02M$650K-$-370K
Income before tax-$-10.84M-$-23.31M-$-21.28M-$-22.91M-$-14.82M
Income tax expense$270K$250K-$-2.43M$370K$380K
Net income-$-11.21M-$-23.46M-$-18.71M-$-23.18M-$-15.17M
Weighted average shares outstanding$42.2M$35.5M$34.6M$34.5M$34.3M
Weighted average diluted shares outstanding$42.2M$35.5M$34.6M$34.5M$34.3M
Balance sheet
20252024202320222021
Cash and short-term investments$31.7M$31.7M$43.7M$10.2M$30.9M
Net receivables$16.8M$15.5M$14M$18.3M$21.2M
Inventory$8.6M$7.56M$9.92M$11.8M$6.78M
Total current assets$58.5M$56.4M$70.4M$43M$60.7M
Property, plant and equipment, net$6.62M$6.74M$7.15M$7.59M$6.87M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.37M$8.4M$8.88M$8.8M$7.98M
Total assets$66.8M$64.8M$79.2M$51.8M$68.7M
Accounts payable$3.06M$2.62M$2.71M$2.67M$2.63M
Short-term debt$430K$350K$370K$250K$290K
Deferred revenue$0.00$690K$490K$850K$530K
Total current liabilities$11.7M$10.7M$12.7M$11.9M$13.2M
Long-term debt$38.9M$38.4M$38.1M$540K$20K
Deferred revenue, non-current$1.05M$1.12M$1.25M$1.41M$1.32M
Total non-current liabilities$40.3M$39.8M$39.6M$2.13M$1.51M
Capital lease obligations$4.49M$4.52M$5.32M$800K$300K
Total liabilities$52M$50.5M$52.3M$14M$14.7M
Common stock$40K$40K$40K$40K$30K
Retained earnings-$-89.12M-$-77.91M-$-54.45M-$-35.73M-$-12.55M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$14.8M$14.3M$26.9M$37.8M$54M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$39.3M$38.8M$38.5M$800K$300K
Net debt$7.6M$7.02M-$-5.15M-$-9.4M-$-30.57M
Cash flow statement
20252024202320222021
Net income-$-11.11M-$-23.56M-$-18.85M-$-23.28M-$-15.2M
Depreciation and amortization$660K$600K$690K$890K$900K
Stock-based compensation$2M$4.01M$5.11M$6.7M$5.09M
Change in working capital-$-1.59M-$-1.25M$5.54M-$-5.22M-$-1.84M
Accounts receivable-$-1.32M-$-2.04M$3.97M$1.92M-$-4.9M
Inventory-$-1.07M$2.26M$1.46M-$-5.57M-$-2.86M
Accounts payable$350K-$-60K$30K$70K$1.15M
Net cash provided by operating activities-$-8M-$-18.05M-$-5.25M-$-20.28M-$-10.45M
Investments in property, plant and equipment-$-1.11M-$-720K-$-530K-$-1.01M-$-720K
Acquisitions, net$0.00$0.00$7.41M$0.00$200K
Net cash used for investing activities-$-1.11M-$-720K$6.73M-$-1.01M-$-720K
Common stock issued$9.54M$7M$2.72M$360K$70K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.58M$6.75M$32.2M$220K$20K
Net change in cash-$0.00-$-11.91M$33.5M-$-20.68M-$-11.04M
Cash at end of period$31.7M$31.7M$43.7M$10.2M$30.9M
Operating cash flow-$-8M-$-18.05M-$-5.25M-$-20.28M-$-10.45M
Capital expenditure-$-1.11M-$-720K-$-530K-$-1.01M-$-720K
Free cash flow-$-9.12M-$-18.77M-$-5.78M-$-21.29M-$-11.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Apyx Medical Corporation

        Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

        CEO
        Charles D. Goodwin
        Employees
        205
        Beta
        1.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Apyx Medical Corporation (APYX)?

        Apyx Medical Corporation (APYX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is APYX undervalued?

        APYX trades at a price of $2.40 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.